Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2014

01.10.2014 | Original Article

Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan

verfasst von: Hiroyasu Yamashiro, Masahiro Takada, Eiji Nakatani, Shiro Imai, Akira Yamauchi, Shigeru Tsuyuki, Yasuo Matsutani, Shingo Sakata, Yasuo Wada, Ryuji Okamura, Tomika Harada, Fumie Tanaka, Yoshio Moriguchi, Hironori Kato, Shunichi Higashide, Norimichi Kan, Hiroshi Yoshibayashi, Hirofumi Suwa, Takashi Okino, Ichiro Nakayama, You Ichinose, Kazuhiko Yamagami, Takashi Hashimoto, Takashi Inamoto, Masakazu Toi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Bone metastasis (BM) is important for studying systemic spread of breast cancer. It often causes skeletal-related events (SREs) that worsen quality of life. We investigated the prevalence and risk factors for BM and SRE using a dataset from the Breast Oncology Research Network (BORN) in Japan.

Patients and methods

We collected data on primary breast cancer patients with node-positive or node-negative disease at intermediate to high risk of recurrence. The risk factors affecting the BM-free rate, SRE-free rate and overall survival were analyzed by using the Cox proportional hazard model.

Results

Data of 1,779 patients who were diagnosed with breast cancer during 2003–2005 were collected from the BORN and 1,708 cases were used for analysis. The median follow-up duration was 5.71 years. BM developed in 193 cases (11.3 %) and the BM-free rate at 5 years was 89.2 %. The annual hazard ratio of BM development differs remarkably according to the tumor subtype. SREs occurred in 133 (68.9 %) out of 193 patients and the SRE-free rate at 5 years was 92.6 %. In the multivariate analysis, clinical stage (P < 0.0001), number of lymph node (LN) metastases (P = 0.0029), tumor subtype (P = 0.034) and progesterone receptor status (P = 0.038) were independently significant risk factors for BM-free rate, but only clinical stage (P < 0.0001) and number of LN metastases (P = 0.0004) significantly correlated with SRE-free rate.

Conclusions

This retrospective study clarifies the prevalence and risk factors for BM and SRE in Japanese breast cancer patients. Our results show the importance of considering subtype in the care of BM and SRE.
Literatur
1.
Zurück zum Zitat Liang Y, Wu H, Lei R et al (2012) Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem 287:33533–33544PubMedCrossRefPubMedCentral Liang Y, Wu H, Lei R et al (2012) Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem 287:33533–33544PubMedCrossRefPubMedCentral
2.
Zurück zum Zitat Bidwell BN, Slaney CY, Withana NP et al (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18(8):1224–1231PubMedCrossRef Bidwell BN, Slaney CY, Withana NP et al (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18(8):1224–1231PubMedCrossRef
3.
Zurück zum Zitat Yao Y, Fang ZP, Chen H et al (2012) HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway. Cancer Gene Ther 19:601–608PubMedCrossRef Yao Y, Fang ZP, Chen H et al (2012) HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway. Cancer Gene Ther 19:601–608PubMedCrossRef
4.
Zurück zum Zitat Gibert B, Eckel B, Gonin V et al (2012) Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 107:63–70PubMedCrossRefPubMedCentral Gibert B, Eckel B, Gonin V et al (2012) Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 107:63–70PubMedCrossRefPubMedCentral
5.
Zurück zum Zitat Khatcheressian JL, Hurley P, Bantug E et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 31(7):961–965PubMedCrossRef Khatcheressian JL, Hurley P, Bantug E et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 31(7):961–965PubMedCrossRef
6.
Zurück zum Zitat Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157PubMedCrossRef Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157PubMedCrossRef
7.
Zurück zum Zitat Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691PubMedCrossRef Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691PubMedCrossRef
8.
Zurück zum Zitat Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139PubMedCrossRef Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139PubMedCrossRef
9.
Zurück zum Zitat Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227PubMedCrossRef Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227PubMedCrossRef
10.
Zurück zum Zitat Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474PubMed Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474PubMed
11.
Zurück zum Zitat Major PP, Cook RJ, Lipton A et al (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272PubMedCrossRefPubMedCentral Major PP, Cook RJ, Lipton A et al (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272PubMedCrossRefPubMedCentral
12.
Zurück zum Zitat Metzger-Filho O, Sun Z, Viale G et al (2013) Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from International Breast Cancer Study Group Trials VIII and IX. J Clin Oncol 31(25): 3083–90. Metzger-Filho O, Sun Z, Viale G et al (2013) Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from International Breast Cancer Study Group Trials VIII and IX. J Clin Oncol 31(25): 3083–90.
13.
Zurück zum Zitat Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277PubMedCrossRef Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277PubMedCrossRef
14.
15.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef
16.
Zurück zum Zitat Kiba T, Inamoto T, Nishimura T et al (2008) The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I–III) 3 years after surgery. BMC Cancer 8:323PubMedCrossRefPubMedCentral Kiba T, Inamoto T, Nishimura T et al (2008) The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I–III) 3 years after surgery. BMC Cancer 8:323PubMedCrossRefPubMedCentral
17.
Zurück zum Zitat Alanko A, Heinonen E, Scheinin T et al (1985) Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56:1696–1700PubMedCrossRef Alanko A, Heinonen E, Scheinin T et al (1985) Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56:1696–1700PubMedCrossRef
18.
Zurück zum Zitat Hess KR, Pusztai L, Buzdar AU et al (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105–118PubMedCrossRef Hess KR, Pusztai L, Buzdar AU et al (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105–118PubMedCrossRef
Metadaten
Titel
Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan
verfasst von
Hiroyasu Yamashiro
Masahiro Takada
Eiji Nakatani
Shiro Imai
Akira Yamauchi
Shigeru Tsuyuki
Yasuo Matsutani
Shingo Sakata
Yasuo Wada
Ryuji Okamura
Tomika Harada
Fumie Tanaka
Yoshio Moriguchi
Hironori Kato
Shunichi Higashide
Norimichi Kan
Hiroshi Yoshibayashi
Hirofumi Suwa
Takashi Okino
Ichiro Nakayama
You Ichinose
Kazuhiko Yamagami
Takashi Hashimoto
Takashi Inamoto
Masakazu Toi
Publikationsdatum
01.10.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0643-5

Weitere Artikel der Ausgabe 5/2014

International Journal of Clinical Oncology 5/2014 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.